2022 - NfL in Real-World Clinical Settings
Date2022-10-27
Deadline2022-10-27
VenueWebinar, USA - United States
KeywordsNeurodegenerative Disease; Laboratory Testing; Neurology
Topics/Call fo Papers
Neurofilament light chain (NfL) protein has been well studied in a broad array of neurodegenerative diseases for years, and yet the specific parameters of its use in clinical settings have not yet been well established. Recently, Labcorp made NfL widely available as an orderable lab test for clinicians nationwide, but its prior unavailability has left questions about how it can be practically employed in patient workups and monitoring. Still, clinicians are beginning to use NfL and are learning about how it can provide useful and important information for patient care.
Register to understand what neurofilament light chain is and its importance in neurology, and ways that it may be practically used in patients with multiple sclerosis, concussion and amyotrophic lateral sclerosis (ALS).
Register to understand what neurofilament light chain is and its importance in neurology, and ways that it may be practically used in patients with multiple sclerosis, concussion and amyotrophic lateral sclerosis (ALS).
Other CFPs
- Time for Change in NASH: How Non-Invasive Biomarkers are Driving a Paradigm Shift in Clinical Trials and Clinical Care
- Getting Your Asset into the Global Market: Regulatory, Clinical and Commercial Considerations
- Imaging in Clinical Trials: Pitfalls and Promises
- What Clinical Trial Participants Want — And How Sponsors can Deliver
- The Strategic and Scientific Imperative for Prospectively Generated Real-World Evidence
Last modified: 2022-10-05 02:41:59